HEALWELL AI has an upside of 252%, Haywood says

Haywood Securities’ June 13 report argues that HealWELL AI (HealWELL Stock Quote, Chart, News, Analysts, Financials TSXV:AIDX) is well-positioned to capitalize on the rapid growth of AI in healthcare, especially in preventative care and early disease detection.

Analyst Gianluca Tucci is maintaining a “Buy” rating and a C$4.50 price target, implying a 252% upside from the current share price of C$1.28.

Tucci said HealWELL is a top pick for investors seeking exposure to the digital health and AI transformation wave, especially as cross-selling into Orion’s base gains traction.

HealWELL is a healthcare AI company focused on improving preventative care and early disease detection. It develops AI tools that help providers identify high-risk patients and improve outcomes, supported by clinical data and strategic partnerships.

HealWELL’s AI tools aim to reduce administrative burdens, improve diagnostic accuracy, and free up physician time, helping to shift healthcare from a reactive to a proactive approach. Its exclusive partnership with WELL Health gives it access to 40,000 clinicians and millions of patient records annually. The recent acquisition of Orion Health adds $100-million in high-margin SaaS revenue and deepens U.S. market access. Other acquisitions (e.g., Pentavere, BioPharma) expand capabilities across AI, clinical research, and data interoperability.

“With a core focus on preventative care and early disease detection, HealWELL isn’t just riding the wave – it’s actively shaping it,” Tucci said. “Through its proprietary AI clinical co-pilot tools, the company is empowering healthcare providers to detect rare and chronic diseases earlier, a critical step towards improving patient outcomes and reducing systemic healthcare costs. This proactive approach directly addresses the growing demand for solutions that move beyond reactive treatment to truly predictive and preventative health management.”

Haywood expects HealWELL to generate $136-million in revenue and $4.1-million in Adjusted EBITDA in 2025, increasing to $190.9-million and $18.5-million, respectively, in 2026.

Backed by strong industry tailwinds, AIDX is well-positioned to benefit from the rising demand for AI in healthcare. As of 2023, the global market for healthcare AI was estimated at approximately US$15.1-billion and is projected to grow at a 37–42% CAGR, reaching between US$102.7-billion and US$107.5-billion by 2030, according to Fortune Business Insights and Grand View Research.

“We believe the market is awaiting early evidence of AI cross-sell into Orion’s established customer base,” Tucci said. “A recent HealWELL fireside chat highlighted two specific proof of concepts underway which would illustrate this cross-sell, which we believe would be material to results if successfully converted and ignite a re-rate in its equity.”

Disclosure: Nick Waddell owns shares of AIDX.

-30-